Biohaven Pharmaceutical Holding Co Ltd. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Product revenue, net
Cost of goods sold
Gross profit
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest expense
Interest expense on mandatorily redeemable preferred shares
Interest expense on liability related to sale of future royalties
Change in fair value of warrant liability
Change in fair value of contingent equity liability
Change in fair value of derivatives
Gain (loss) from equity method investment
Other expense, net
Total other expense
Loss before provision for income taxes
Provision for income taxes
Net loss
Accretion of beneficial conversion feature on Series A preferred shares
Less: Net loss attributable to non-controlling interests
Net loss attributable to Biohaven Pharmaceutical Holding Company Ltd.
Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd.—basic (in dollars per share)
Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd.—diluted (in dollars per share)
Weighted average common shares outstanding—basic
Weighted average common shares outstanding—diluted

Comments